 CARMIEL, Israel, May 14, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. While the receipt of the Complete Response Letter last month from the FDA was disappointing, we are encouraged that the FDA did not report any potential safety or efficacy concerns for PRX-102, said Dror Bashan, Protalixs President and Chief Executive Officer. 